Acelrx Pharmaceuticals FY 2020: net loss $40.4M
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001437749-21-006074
- Document
- 10-K
- Exhibit 4.1
- Warrants or notes
- Exhibit 10.17
- Material contract
- Exhibit 10.18
- Material contract
Key figures from this report
These are the numbers Acelrx Pharmaceuticals reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Net income−$40.4MNo year-earlier figure tagged10-K income statement, on EDGAR
- Cash and cash equivalents$27.3MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$38.5MNo year-earlier figure tagged10-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Biovie BIVI public float $8M, Dec 31, 2025
- Processa Pharmaceuticals PCSA public float $8M, Jun 30, 2025
- GT Biopharma GTBP public float $9M, Jun 30, 2025
- Orgenesis ORGS public float $8M, Jun 30, 2025
- TherapeuticsMD TXMD public float $9M, Jun 30, 2025